(Image: Associated Press)
Novo dumps proposed Rybelsus successor for newer model
Barely over a month after gaining FDA approval for the first GLP-1 drug Rybelsus, Novo Nordisk is dumping the compound it had been developing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
